IVERIC Bio, An Astellas Company, is a leading biopharmaceutical brand dedicated to developing transformative therapies for retinal diseases. With a focus on addressing significant unmet medical needs, IVERIC Bio is at the forefront of discovering and advancing treatments for conditions such as Geographic Atrophy, Stargardt Disease, and Inherited Retinal Diseases. Our experienced and passionate team is committed to collaborative clinical development and commercialization of novel therapies, with the goal of improving the lives of patients and eyecare professionals.

Our strategy involves developing multiple assets, including avacincaptad pegol and IC-500, to treat a broad spectrum of retinal diseases, including AMD, the leading cause of vision loss in the elderly. Moreover, we are proud to be exploring novel gene therapy technology to address orphan inherited retinal diseases. Through our dedication to innovation, expertise in ophthalmology, and commitment to patients, IVERIC Bio is poised to make a meaningful impact in the field of retinal diseases